AstraZeneca Plc’s diabetes drug significantly reduced blood sugar levels in a late-stage study in adolescents aged 10–17 with type 2 diabetes, the UK-based drugmaker said on Friday.
Data from the study was presented at the 2021 American Diabetes Association (ADA) Virtual 81st Scientific Sessions.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
